Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Mylan Pharmaceuticals, a subsidiary of Mylan Inc, has introduced Bromfenac Ophthalmic Solution, 0.09% (Twice Daily Administration), under its supply and development pact with Coastal Pharmaceuticals.
Subscribe to our email newsletter
Bromfenac Ophthalmic Solution, 0.09% is the generic version of ISTA’s Xibrom Ophthalmic Solution, 0.09%.
Xibrom is indicated for the treatment of postoperative inflammation and the reduction of ocular pain in patients who have undergone cataract extraction.
Each ml of Xibrom contains 1.035mg bromfenac sodium (equivalent to 0.9 mg bromfenac free acid).